

Table 1 Description of the studies included – Inclusion and exclusion criteria and sample description

Year First Author Country	Type of UI	Inclusion Criteria	Exclusion Criteria	No of Patients included	Age (Years) BMI Kg/m ²) Parity (n)
2018 Fistonic I Croatia	SUI	<ul style="list-style-type: none"> - SUI; - History of vaginal delivery; - Normal cell cytology; - Negative urine culture; - No vulvar or vaginal injuries; - Failure of pelvic floor muscle training. 	<ul style="list-style-type: none"> - Photosensitive disorder or use of photosensitizing drugs; - POP-Q stage \geq II; - UUI; - Severe neurological conditions associated with incontinence; - Neurogenic bladder; - Insulin-dependent diabetes mellitus; - Actual urinary tract infection; - Haematuria; - Age <18 and >70 years; - Pregnancy; - Vaginal delivery within the last 24 weeks; - BMI ≥ 35 kg/m²; - Injury or/and active infection in the treatment area; - Undiagnosed vaginal bleeding. 	<p>Total: 88 With UI: 88 Lost to follow-up: 4</p> <p>Age 48 (41-54) BMI 23 (21-26) Parity 2 (2-2)</p> <p>Median (IQR)</p>	
2017 Behnia-Willison Australia	UII	<ul style="list-style-type: none"> - Postmenopausal Women not responding or not able to do conventional treatment; - With dyspareunia or vaginal dryness. 	<ul style="list-style-type: none"> - Unexplained bleeding; - Abnormal pap-smear; - Active genital infections; - Active urogenital cancer. 	<p>Total: 102 With UI: NA Lost to follow-up: NA</p> <p>Age 61\pm7 BMI NA</p> <p>Parity NA</p>	

						Mean±SD
2017 Gaspar A.Argentina	SUI (type III)	- Type III SUI; - Valsalva leak point pressure (VLPP) of 20–60 cm H ₂ O.	- Patients taking alpha-blockers medication; - Previous pelvic radiotherapy or pelvic surgery;	Total: 22 With UI: 22	Age 57.9 (33-66)	
				Lost to follow-up:0	BMI 27.3 (23-30)	
					Parity NA	
					Mean (Range)	
2017 González- Isaza P. Colombia	SUI	- Mild SUI; - Postmenopausal women.	- Anterior Compartment POP-Q stage > II; - Previous surgery; - Recurrent lower urinary tract infection; - BMI >35 kg/m ² .	Total: 161 With UI: 161 Lost to follow-up:0	Age 53±5,1 BMI <35 Parity 2.5±1	
					Mean±SD	
2017 Lapii GA Russia	SUI	- Vaginal wall prolapse.	- NA	Total: 18 With UI: 18 Lost to follow-up: NA	Age 49±12,5 BMI NA Parity NA	
					Mean±SD	
2017 Lapii GA Russia	SUI	- Vaginal wall prolapse (POP-Q stage <3).	- NA	Total: 98 With UI: 98 With biopsy: 18	Age 49±12,5 BMI	

				Lost to follow-up: NA	NA
				Parity NA	Parity NA
				Mean±SD	Mean±SD
2017 Lin YH Taiwan	SUI (with / without OAB)	- SUI; - OAB symptoms.	- Urinary tract infection; - POP-Q stage > II; - Pregnancy; - Haematuria; - Childbirth within one year; - Abnormal vaginal bleeding; - Damage of vaginal fascia; - History of spinal cord injury; - Post radical hysterectomy; - Stroke; - Autoimmune disease; - 1-h pad test > 50g.	Total: 30 With UI: 30 Lost to follow-up: 0	Age 52.6±8.8 BMI 24.5±3.3 Parity 2.5±0.9 Mean±SD
2017 Pagano I Italy	SUI	- Vaginal atrophy with/or SUI (type 1 or 2); - Negative Pap smear during last 12 months.	- Active urogenital cancer - Active urogenital infection - Urge or mixed incontinence - POP-Q stage > II; - Allergy to LASER.	Total: 33 With UI: 17 Lost to follow-up: NA	Age 52.3±9.9 BMI NA Parity NA Mean±SD
2016 Fistonić N. Croatia	SUI	- History of vaginal delivery; - SUI	- Severe prolapse and damage of the recto-vaginal fascia; - UUI;	Total: 31 With UI: 31	Age 46.8±9.1

		<ul style="list-style-type: none"> - Normal cell cytology; - Negative urine culture; - No local injuries and bleeding. 	<ul style="list-style-type: none"> - Severe neurological conditions associated with incontinence; - Neurogenic bladder; - Insulin-dependent diabetes mellitus; - Urinary tract infection; - Hematuria; - Age \leq18 and $>$70 years; - Pregnancy; - Less than 24 weeks after vaginal delivery; - BMI $>$30; - Intake of photosensitive drugs; - Local Injury or/and active infection; - Undiagnosed vaginal bleeding. 	<p>Lost to follow-up: 17</p> <p>BMI: 23.3\pm2.7</p> <p>Parity: Mean\pmSD</p> <p>2 (1.7-3)</p> <p>Median (IQR)</p>
2016 Pardo JI. Chile	SUI	- Mild to severe SUI.	<ul style="list-style-type: none"> - Exclusive UUI; - Severe prolapse; - Pregnancy; - Previous surgery due to treated condition; - Patients with severe neurological conditions; - Vaginal lesions; - Genitourinary tract infections; - Abnormal vaginal bleeding; - History of photosensitivity disorder or use of photosensitizing drugs; - Hematuria. 	<p>Total: 42</p> <p>With UI: 42</p> <p>Lost to follow-up: 0</p> <p>Age: 46.5 (30-79)</p> <p>BMI: NA</p> <p>Parity: 2 (0-5)</p> <p>Median (Range)</p>
2016 Perino A. Italy	UUI	<ul style="list-style-type: none"> - Post-Menopausal women; - \geq 1 vulvovaginal symptoms Non-response to previous estrogen or local therapies; - OAB 	<ul style="list-style-type: none"> - Clinically significant bladder outflow obstruction; - Post-void residual (PVR) volume $>$200ml; - associated SUI; - Diabetic neuropathy; - Use of concomitant urinary incontinence or psychotropic 	<p>Total: 30</p> <p>With UI: 9</p> <p>Lost to follow-up: 0</p> <p>Age: 56 (8.5)</p> <p>BMI: 23.9 (3.49)</p> <p>Parity</p>

			medications;			
			- Symptomatic urinary tract infection;	1 (1.25)		
			- Active genital infections;	Median (IQR)		
			- Previous pelvic radiation therapy;			
			- Previous or current malignant disease of the pelvic organs;			
			- POP-Q stage.>II;			
			- Use of any form of HRT within the previous 6 months.			
2016 Pitsouni E. Greece	UUI	- Menopause; - ³¹ symptom of genitourinary syndrome of menopause (GSM) with moderate-severe intensity and clinical signs of GSM.	- Use of any form of hormone therapy (HRT) within the previous 6 months;	Total: 53	Age	
			- Use of lubricants or vaginal moisturizers within the last month;	With UI: 53	57.2±5.4	
			- Active genital infections;	Lost to follow-up:0	BMI	
			- POP-Q stage ≥ II.		26.0±4.8	
					Parity	
					NA	
					Mean±SD	
2016 Tien YW. Taiwan	SUI (with / without OAB)	- SUI; - Sexually active.	- Undiagnosed abnormal vaginal bleeding.	Total: 35	Age	
				With UI: 35	43.3±7.2	
				Lost to follow-up:2	BMI	
					24.0±3.2	
					Parity	
					1.8±1.2	
					Mean±SD	
2015 Gambacciani M.a Italy	SUI	- Post menopausal women; - Genitourinary syndrome; - FSH > 40U/L, E2<25pg/mL; - Negative pap smear.	- Vaginal lesions or scars; - Active or recent (30 days) genitourinary tract infections; - Abnormal uterine bleeding; - Use of lubricants or any other local preparations 30 days before	Total: 45	Age	
				With UI: 19	60.9±8.1	
				Lost to follow-up:2	BMI	
					26.1±3.3	

			- History of photosensitivity disorder or use of photosensitizing drugs;	Parity
			- POP-Q stage \geq II;	$12,5 \pm 5,8$
			- Serious or chronic condition that could interfere with study compliance;	Mean \pm SD
			- Treatment with medicines to relieve menopausal symptoms 12 months before.	
2015 Gambacciani M.b Italy	SUI	<ul style="list-style-type: none"> - Post menopausal women; - Genitourinary syndrome; - FSH > 40U/L, E2<25pg/mL; - Negative pap smear. 	<ul style="list-style-type: none"> - Vaginal lesions or scars; - Active or recent (30 days) genitourinary tract infections; - Abnormal uterine bleeding; - Use of lubricants or any other local preparations 30 days before - History of photosensitivity disorder or use of photosensitizing drugs; - POP-Q stage \geqII; - Serious or chronic condition that could interfere with study compliance; - Treatment with medicines to relieve menopausal symptoms 12 months before. 	<p>Total: 69 Age</p> <p>With UI: 21 62.9 ± 8.1</p> <p>Lost to follow-up: 2 BMI</p> <p>27.5 ± 2.3</p> <p>Parity</p> <p>NA</p> <p>Mean \pm SD</p>
2015 Fistonić N. Croatia	SUI	<ul style="list-style-type: none"> - History of vaginal delivery; - SUI; - Normal cell cytology; - Negative urine culture; - Free of local injuries or bleeding. 	<ul style="list-style-type: none"> - Severe prolapse and damage of the recto vaginal fascia; - UUI; - Severe neurological conditions associated with incontinence; - Neurogenic bladder; - Insulin-dependent diabetes mellitus; - Actual urinary tract infection; - Hematuria; - Age \leq18 and $>$70 years; - Pregnancy; - Less than 24 weeks after vaginal delivery; - BMI $>$ 35kg/m²; - Intake of photosensitive drugs; - Injury or/and active infection in the treatment area; 	<p>Total: 73 Age</p> <p>With UI: 73 $47 (41-54)$</p> <p>Lost to follow-up: 28 BMI</p> <p>$23 (21-25)$</p> <p>Parity</p> <p>2 (2-3)</p> <p>Median (IQR)</p>

			- Undiagnosed vaginal bleeding.		
2015 Ogrinc UB. Slovenia	SUI and MUI	<ul style="list-style-type: none"> - Clinically confirmed UI; - Normal PAP smear; - Negative urine culture; - Integrity of the vaginal mucosa. 	<ul style="list-style-type: none"> - Pregnancy; - Intake of photosensitive drugs; - Injuries or vaginal bleeding; - Infection in the treated area; - Pure UUI. 	Total: 175 With UI: 175 Lost to follow-up: 0	Age 49.7 ± 10 Mean \pm SD BMI <ul style="list-style-type: none"> - Underweight 2% - Normal 58% - Overweight 29% - Obese 12% Parity NA

NA, Not Applicable; BMI, Body Mass Index; UI, Urinary Incontinence; SUI, Stress UI; MUI, Mixed UI; UU, Urge UI; OAB, Overactive Bladder; SD, Standard Deviation; IQR, Interquartile Range; POP-Q, Pelvic Organ Prolapse Quantification

Table 2 Description of the studies included – Laser protocol, follow-up, Primary and secondary outcomes

Year First Author Country	LASER Protocol	Follow-up	Patient Reported Outcomes (Questionnaires)	Other Outcomes	Safety / Adverse Effects
2018 Fistonic I Croatia	LASER: Er:YAG	Baseline, F1: 2-6 months. Sessions: 1 Interval: - Anaesthesia: NA Concomitant Therapies: NA Sexual abstinence: NA	ICIQ-UI-SF score B: 12.0 (7.5-16.0) F1: 6 (0-11) ($p < 0.001$) Median (IQR)	Q-tip test (degrees) – Valsalva Manoeuvre B: 72.5 (48.8-80) F1: 50 (30-70) ($p < 0.001$) Residual Volume (mL)	During Sessions: NA After treatment: NA

			Basal Q-tip test Basal ICIQ-UI test Non predictors of greater ICIQ-score improvement: Parity Birth weight Menopause Basal Perineometry	Perineometry – Avarage (mmHg) B: 5.3 (4.2-7.3) F1: 6.4 (4.8-11.1) (p=0.018) Perineometry – Maximum (mmHg) B: 10.5 (8-14) F1: 11.3 (8.4-17.8) (p=0.001) Perineometry – Duration (seconds) B: 8.5 (5-14.3) F1: 12.1 (6.1-18.3) (p=0.001) Median (IQR)	
2017 Behnia-Willison Australia	LASER: CO2 Sessions: 3 Interval: ≥ 6 weeks Anaesthesia: No Concomitant Therapies: vulvar silicon-based balm post procedure Sexual abstinence: 5 days	Baseline, F1: after last treatment, F2: 12-24 months.	Subjective Evaluation of UUI improvement F1 to F2: 51% (p=0.003) F2 to F3: 53% (p<0.001) Percentage of patients that improved	NA	During Sessions: NA After treatment: Postcoital urinary tract infection (2.9%) Vaginal discharge (1.9%) Transient pelvic pain (2.9%) Herpes Brakout (1%) Postmenopausal bleeding (1.9%)
2017 Gaspar A. Argentina	LASER: Er:YAG Sessions: 2 Interval: 3 weeks Anaesthesia: No	Baseline, F1: 3 months, F2: 6 months.	ICIQ-UI-SF score B: 18 F1: 5 (p<0.001) F2: 8 (p<0.001)	1-h pad weight test B: 23g F1: 10g 18 (82%) (p<0.001) F2: 14g 11 (50%) (p<0.001)	During Sessions: Well tolerated After laser therapy:

	Concomitant Therapies: vitamin C 2 g/day for 3 months; vitamin A 50,000 UI/day for 3 months; ciprofloxacin 1g 2h before intervention. Local estriol before treatment (when needed) Sexual abstinence: 3 days	Mean (significance is versus Baseline)	Pad weight mean number of patients that improved (%) (significance is versus Baseline)	pelvic pain (n=1), dysuria (n=2). Both effects disappeared within 24h
2017 González- Isaza P. Colombia	LASER: CO ₂ Sessions: 4 Interval: 30-45d Anaesthesia: NA Concomitant Therapies: 36% under HRT Sexual abstinence: NA	Baseline, F1: 12 months, F2: 24 months, F3: 36 months. ICIQ-UI-SF score B: 14.34±2.65 F1: 7.09±1.1 (p<0.001) F2: 7.49±0.94 (p<0.001) F3: 6.76±0.82 (p<0.001) Mean±SD (significance is versus Baseline)	1-h pad weight test B: 9.89±0.57g F1: 3.52±1.89g (p<0.001) F2: 3.55±1.88g (p<0.001) F3: 3.72±2.05g (p<0.001) Mean ±SD (significance is versus Baseline) (NS if compared F1-F2, F2-F3, F1-F3) Histologic Examination 6 weeks after: Thicker epithelium with a higher population of intermediate and shedding superficial cells. The stroma with features indicating structural recovery.	Well tolerated. No side effects.
2017 Lapii Gaa Russia	LASER: Er:YAG Sessions: 1 Interval: - Anaesthesia: NA Concomitant Therapies: N/A	Baseline, F1: 1,5-2 months. NA	Index of Ki-67 (Proliferative activity) NA B: 19.05±2.86% F1: 31.79±2.25 (p<0.05) Mean ±SD	

Sexual abstinence: NA					
2017 Lapii Gab Russia	LASER: Er:YAG Sessions: 2 Interval: 1-1.5 months Anaesthesia: NA Concomitant Therapies: N/A Sexual abstinence: NA	Baseline, F1: 1,5-2 months.	NA	Thickness of the Epithelium B: $114.19 \pm 17.31 \mu\text{m}$ F1: $187.83 \pm 15.35 \mu\text{m}$ (p<0.05) Volume density of capillaries B: $1.8 \pm 0.2\%$ F1: $2.9 \pm 0.3\%$ (p<0.01) Number of capillary profiles B: 8.5 ± 0.63 F1: 12.1 ± 1.07 (p<0.05) Vessels diameter B: $6.43 \pm 0.33 \mu\text{m}$ F1: $7.14 \pm 0.35 \mu\text{m}$ (NS) Mean±SD	NA
2017 Lin YH Taiwan	LASER: Er:YAG Sessions: 2 Interval: 4 weeks Anaesthesia: No Concomitant Therapies: N/A Sexual abstinence: 3 days	Baseline, F1: 1 month, F2: 3 months, F3: 12 months.	ICIQ-UI-SF score B: 10.0 ± 3.7 F1: 7.1 ± 4.0 F2: 6.8 ± 4.0 (p=0.002) F3: 5.5 ± 4.2 (p=0.001) OAB symptom score B: 8.2 ± 5.0	1-h pad weight test B: $13.2 \pm 17.7 \text{g}$ F1: $9.7 \pm 15.1 \text{g}$ F2: $6.1 \pm 11.6 \text{g}$ (p=0.039) Mean±SD (significance is versus Baseline)	Major Events: None During Sessions: Mild tolerable pain; burning sensation. [VAS pain score 4.2 ± 2.0] After treatment: Few patients with transient increased vaginal discharge, spotting.

			F1: 7.1±2.1 F2: 6.1±4.3 (p=0.027) F2: 7.9±6.0 (NS) UDI-6 score B: 8.9±4.3 F1: 6.6±3.7 F2: 5.4±3.6 (p<.001) F2: 7.3±4.6 (NS) IIQ-7 score B: 6.9±6 F1: 6.9±5.9 F2: 5.1±5.2 (NS) F2: 6.5±8.3 (NS) Mean±SD (significance is versus Baseline)		
2017 Pagano I Italy	LASER: CO2 Sessions: 3	Baseline, F1: 3 months (after last session). Interval: 1 month Anaesthesia: No Concomitant Therapies: NA Sexual abstinence: NA	ICIQ-UI-SF score B: 9.7±4.0 F1: 7.1±4.2 (p<0.05) A - Surgical menopause B: 9.5±4.3 F1: 7.0±3.3 (p<0.05) B – Physiological menopause B: 10.0±4.0 F1: 7.2±5.1 (p<0.05) Mean±SD	Histological examination Significant increase in the thickness and staining of type III collagen of the epithelium	During Sessions: None After treatment: None
2016 Fistonić	LASER: Er:YAG	Baseline,	ICIQ-UI-SF score	Residual Urine:	During Sessions:

N. Croatia	Sessions: 1	F1: 1 month, Interval: - Anesthesia: NA Concomitant Therapies: NA	B: 12.9±5 F1: 6.6±6.1 (p<0.001) F2: 7.6±6.7 (p<0.01) F3: 7.8±5.7 (p<0.05)	B: 3.8 (1.1-10.5) F1: 0.6 (0.1-3.3) (p=0.01) F2: 0.4 (0.2-3.7) (p= 0.04) F3: 1.0 (0.2-3.3) (p=0.07)	Warmth or teasing sensation (all patients) After treatment: Few patients with transient vaginal discharge and slight vulvar edema
		Sexual abstinence: NA	Mean±SD	Median (IQR) Perineometry No statistically significant differences	
2016 Pardo JI. Chile	LASER: Er:YAG	Baseline, Sessions: 2 Interval: 21-28 d	ICIQ-UI-SF score F1: 3-6 months. B: 11 (6) F1: 3 (10) (p < 0.001)	NA	During Sessions: Well tolerated. Some patients with mild pain
		Anesthesia: Topic Concomitant Therapies: Local estriol before treatment (when needed) Sexual abstinence: 3 days	- Complete Healing: 38.1% - Improvement: 78.6 % - No change: 16,7% - Worse: 4,8%	Median (IQR)	After treatment: None
2016 Perino A. Italy	LASER: CO2	Baseline, Sessions: 3 Interval: ≥ 1 month Anesthesia: No Concomitant Therapies: No	OAB-Q-SF score F1: 30 days (after last session). B: 18.5 (4.25) F1: 8 (2.25) (p<0.0001) Median (IQR)	NA	During Sessions: None After treatment None

Sexual abstinence: NA					
2016 Pitsouni E. Greece	LASER: CO2 Sessions: 2 Interval: 1 month Anesthesia: NA Concomitant Therapies: NA	Baseline, F1: 12 weeks.	ICIQ-UI-SF score B: 8.1±5.6 A: 3.4±4.3 (p<0.001) ICIQ-FLUTS score	NA	During Sessions: None After treatment: Temporary (2h) mild irritation of the introitus.
	Sexual abstinence: NA		B: 3.6±2.4 F1: 1.6±1.5 (p<0.001) UDI-6 score B: 30.2±21.4 F1: 11.9±16.6 (p<0.001) Mean±SD		
2016 Tien YW. Taiwan	LASER: Er:YAG Sessions: 1 Interval: - Anesthesia: Topic Concomitant Therapies: NA Sexual abstinence: NA	Baseline, F1: 3 months, F2: 6 months.	PPBC score: B: 2.7±1.0 F1: 2.0±1.2 (p<0.001) F2: 2.0±1.1 (p<0.001) USS score B: 1.3±0.8 F1: 0.6±0.8 (p<0.01) F2: 0.8±0.7 (p=0.01) OAB symptom score B: 4.1±2.8 F1: 3.1±2.9 (p<0.001) F2: 2.7±2.6 (p<0.001) UDI-6 score	20 minutes Pad weight: B: 14.0±18.2g F1: 6.1±13.1g (p<0.001) F2: 3.1±5.6g (p<0.001) Mean±SD (significance is versus Baseline) Urodynamic tests No statistically significant differences	During Sessions: None After treatment: None

			B: 4.1±2.9 F1: 2.8±3.0 (p<0.001) F2: 3.1±3.1 (p<0.001) IIQ-7 score B: 3.2±4.2 F1: 2.2±4.2 (p<0.05) F2: 2.7±4.9 (p<0.05) Mean±SD (significance is versus Baseline)		
2015 Gambacciani M.a Italy	LASER: Er:YAG Sessions: 3	Baseline, F1: 4 weeks, Interval: 1 month Anesthesia: No Concomitant Therapies: NA Sexual abstinence: 1 week	ICIQ-UI-SF score B: 12.0±1.8 F2: 12 weeks, F3: 24 weeks. F1: 5.5±2.6 (P<0.01) F2: 5.5±2.9 (P<0.01) F3: 5.0±2.6 (P<0.01) Mean±SD (significance is versus Baseline)	NA	During Sessions: Discontinuation because of side effects: 3% After treatment: Burning sensation: 2.2%
2015 Gambacciani M.b Italy	LASER: Er:YAG Sessions: 3 Interval: 1 month Anesthesia: No Concomitant Therapies: NA Sexual abstinence: 1 week	Baseline, At each session, F1: 4 weeks (After last session).	ICIQ-UI-SF score No score available Significant improvement at all evaluations comparing to baseline (p<0.01)	NA	During Sessions: NA After treatment NA
2015 Fistonić N. Croatia	LASER: Er:YAG Sessions: 1	Baseline, F1: 1 month,	ICIQ-UI-SF score B: 12.0 (6.0-16.0)	ICIQ-SF score by BMI The decrease was significantly stronger in normal vs. Overweight (p=0.008)	During Sessions: Warmth or pickling sensation

Interval: -	F2: 2-6 months.	F1: 4.0 (0.0-10.8) (p<0.001)	ICIQ-SF score by BMI	After treatment:
Anaesthesia: No		F2: 4.0 (0.0-11.0) (p<0.001)		
Concomitant Therapies: NA		Median (IQR)	The decrease was significantly and inversely correlated with age (p<0.001)	Transient (48h) increased vaginal discharge, Slight vulvar edema
Sexual abstinence: NA		(significance is versus Baseline)		De novo UUI: 1.4%
2015 Ogrinc UB. Slovenia	LASER: Er:YAG	Baseline,	ICIQ-UI-SF (ISI score)	During Sessions:
	Sessions: 2-3	F1: 2 months,	F1 to F2: Statistically significant improvement	Mild discomfort (mean VAS score: 0.5)
	Time: 0, 1, 6m	F2: 6 months,	F2 to F3: No statistically significant differences	Moderate UI: 3.6±1.4 (p<0.001)
	Anaesthesia: No	F3: 12 months.		Severe IU: 5.7±1.8 (p<0.001)
	Concomitant Therapies: No			Very Severe: 8.4±2.6 (p<0.001)
	Sexual abstinence: 1 week			After treatment: Transient UUI: 6.3%
			(Mean±SD)	De novo UUI: 4%
			ICIQ-SF – ISI improvement by type of UI	
			SUI: 77%	
			MUI: 34% (p<0.001)	
			ICIQ-SF – ISI Improvement by age	
			No statistically significant differences	
			UUI appeared de novo in 4%	

NA, not applicable; B, baseline; F, follow-up; BMI, body mass index; SD, standard deviation; IQR, interquartile range; NS, not significant; CO₂, microablative fractional CO₂-laser; Er:YAG, non-ablative photothermal Erbium: YAG-laser; UI, urinary incontinence; UUI, urge UI; ICIQ, international consultation on incontinence questionnaire; ICIQ-UI-SF, ICIQ-urinary incontinence-short form; ICIQ-FLUTS, ICIQ-female low urinary tract symptoms; ISI, incontinence severity index; IIQ-7, incontinence impact questionnaire-7; OAB, overactive bladder; OAB-Q SF, OAB-questionnaire-short form; PPBC, patient perception of bladder condition; UDI-6, urogenital distress inventory-6; USS, urgency severity scale